Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2014, Article ID 607145, 5 pages
http://dx.doi.org/10.1155/2014/607145
Clinical Study

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment

1Department of Orthopaedic Surgery, Kawakita General Hospital, 1-7-3 Asagaya-kita, Suginami-ku, Tokyo 166-8588, Japan
2Department of Orthopaedic Surgery, Sakurakai Hospital, 2-13-1 Senju Sakuragi, Adachi-ku, Tokyo 120-0045, Japan
3Department of Inorganic Materials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan

Received 28 July 2014; Revised 11 October 2014; Accepted 12 October 2014; Published 9 November 2014

Academic Editor: Jun Iwamoto

Copyright © 2014 Mizue Tanaka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. T. Harris, N. B. Watts, H. K. Genant et al., “Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial,” Journal of the American Medical Association, vol. 282, no. 14, pp. 1344–1352, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-Y. Reginster, H. W. Minne, O. H. Sorensen et al., “Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis,” Osteoporosis International, vol. 11, no. 1, pp. 83–91, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. B. J. Gertz, S. D. Holland, W. F. Kline et al., “Studies of the oral bioavailability of alendronate,” Clinical Pharmacology and Therapeutics, vol. 58, no. 3, pp. 288–298, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Itoh, Y. Sekino, K.-I. Shinomiya, and S. Takeda, “The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis,” Journal of Bone and Mineral Metabolism, vol. 31, no. 2, pp. 206–211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Ito, K. Ikeda, M. Nishiguchi et al., “Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk,” Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1828–1836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Ivanovich, H. Fellows, and C. Rich, “The absorption of calcium carbonate.,” Annals of Internal Medicine, vol. 66, no. 5, pp. 917–923, 1967. View at Publisher · View at Google Scholar · View at Scopus
  7. M. S. Sheikh, C. A. Santa Ana, M. J. Nicar, L. R. Schiller, and J. S. Fordtran, “Gastrointestinal absorption of calcium from milk and calcium salts,” The New England Journal of Medicine, vol. 317, no. 9, pp. 532–536, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Kushida, M. Fukunaga, H. Kishimoto et al., “A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial,” Journal of Bone and Mineral Metabolism, vol. 22, no. 5, pp. 469–478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Rizzoli, S. L. Greenspan, G. Bone III et al., “Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis,” Journal of Bone and Mineral Research, vol. 17, no. 11, pp. 1988–1996, 2002. View at Google Scholar
  10. S. Uchida, T. Taniguchi, T. Shimizu et al., “Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study,” Journal of Bone and Mineral Metabolism, vol. 23, no. 5, pp. 382–388, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Kishimoto, M. Fukunaga, K. Kushida et al., “Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen,” Journal of Bone and Mineral Metabolism, vol. 24, no. 5, pp. 405–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Hagino, H. Kishimoto, H. Ohishi, S. Horii, and T. Nakamura, “Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5 mg once-daily dosage regimen,” Bone, vol. 59, pp. 44–52, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Ogura, A. Gonsho, J.-C. Cyong, and H. Orimo, “Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies,” Journal of Bone and Mineral Metabolism, vol. 22, no. 2, pp. 111–119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. W. D. Leslie, J. F. Tsang, P. A. Caetano, and L. M. Lix, “Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 1, pp. 77–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L.-A. Fraser, W. D. Leslie, L. E. Targownik, A. Papaioannou, and J. D. Adachi, “The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study,” Osteoporosis International, vol. 24, no. 4, pp. 1161–1168, 2013. View at Publisher · View at Google Scholar · View at Scopus